Latest by Rob Camp

Following the HIV Primary Care Guidelines: A Walk-Through

To provide a better sense of how to provide primary care for patients living with HIV, here's a walk-through of the HIVMA/IDSA Primary Care Guidelines.

By Rob Camp

A Look at HIV Treatment Guidelines Around the World

Treatment guidelines can vary depending on what part of the world you live in. Treatment activist Rob Camp provides a walk-through on some of the key differences to help clear up any confusion.

By Rob Camp

2007 Antiretrovirals in Development Pipeline

NRTIs, NNRTIs and Protease Inhibitors Entry Inhibitors, Integrase Inhibitors, Maturation Inhibitors and Other Drugs

NRTIs, NNRTIs and Protease InhibitorsPhase of DevelopmentNRTINNRTIPIPreclinicalBPH-218, bis-phosphonate NRTI, U PittsburghC-8 sub...

By Rob Camp for Treatment Action Group

Little Leap: Gilead 2-in-1 Opens Door to Impending One-Pill Triple Combo

GSK's, a Sort of Snoozer

In early August the FDA announced the approvals of two fixed-dose combination (FDC) antiretroviral drug products. FDCs are combinations of two previously approved drugs (à la the Combivir or Trizivir model) in what is unders...

By Rob Camp for Treatment Action Group

Drug Monitoring and Pharmacology: More Mixes Nixed By Concentration Preoccupations

Statin StrengthRelative Potency of the HMG-CoA Reductase Inhibitors (a.k.a. Statins)DrugDaily DoseRelative PotencyFluvastatin (Lescol)60 mg1Pravastatin (Pravachol)60 mg2Lovastatin (Mevacor)20 mg3Simvastatin (Zocor)10 mg6Atorvastat...

By Yasmin Halima and Rob Camp for Treatment Action Group

Tipranavir Pharmacokinetics May Confine Its Use to Limited Rescue Role

Penned in by PK What Is a Salvage Drug? A Look at BI's "51" Study BI "51" Safety and PK Analyses What Is a Salvage Drug? Does Tipranavir Fit the Bill? Is It Time for Expanded Access? TPV/r and Atorvastatin or Antacids TMC114/r and Foo...

By Rob Camp for Treatment Action Group

Where's My Pipeline? Vicissitudes of Medicine and Marketing Take Toll on Me-Too Lineup

B-I the New Salvage Outfit? Nukes Non-Nukes Protease Inhibitors To the Nines: The Parade of Me-Toos

B-I the New Salvage Outfit?

Pipelines are almost as delicate and fragile as the ecosystems they go trampling through, writes TAG's Antivir...

By Rob Camp for Treatment Action Group

Seven (Minus 4, Plus 3) Agents to Fix Your Gaze On

Last year's pipeline report was warm, starry eyed and exuberant. How wrong can one guy be? Blow 1: The close of the year 2003 saw the "on-hold"-ing of SCH-C, the entry inhibitor that was moribund before the ink on the articles describing it was even ...

By Rob Camp for Treatment Action Group

Position Paper on Atazanavir (BMS-232623, Reyataz)

Introduction Overview This paper will discuss the following issues: Executive Summary Follow-Up Studies That Need to Be Done Pre-Clinical Data Pharmacokinetics & Dosing The Inhibitory Quotient Side Effects ...

By Rob Camp for Treatment Action Group

FTC Has Been Approved: What Now?

A Co-Formulation Elation?

Earlier this month, the fluoronated 3TC agent, FTC (emtricitabine, Emtriva) received FDA approval for the treatment of HIV in adults. The latest once-daily nuke on the block (now that Gilead has acquired the drug from Trian...

By Rob Camp for Treatment Action Group